Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · CFR · Title 21 — Food and Drugs · Part 882 — Neurological Devices · § 882.5705

§ 882.5705. Digital therapy device to reduce sleep disturbance for psychiatric conditions.

276 words·~1 min read·/us/cfr/t21/s§ 882.5705·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Identification. A digital therapy device to reduce sleep disturbance for psychiatric conditions is a prescription device that is intended to provide stimulation using a general purpose computing platform to reduce sleep disturbance in patients who experience this symptom due to psychiatric conditions such as nightmare disorder or post-traumatic stress disorder.
(b)Classification. Class II (special controls). The special controls for this device are:
(1)Clinical performance testing under the labeled conditions for use must evaluate the following:
(i)The ability of the device to provide therapy for patients with sleep disturbance due to psychiatric conditions, using a validated measure;
(ii)Worsening of any condition-specific symptoms using a validated measure for assessment of the particular condition; and
(iii)Increase in symptoms of disturbed sleep or sleepiness using a validated measure.
(2)Software must clearly describe all features and functions of the software implementing the digital therapy. Software verification, validation, and hazard analysis must also be provided.
(3)The labeling must include the following:
(i)Patient and physician labeling must include instructions for use, including images that demonstrate how to interact with the device;
(ii)Patient and physician labeling must list the minimum operating system and general purpose computing requirements that support the software of the device;
(iii)Patient and physician labeling must include a warning that the digital therapy device is not intended for use as a stand-alone therapeutic device;
(iv)Patient and physician labeling must include a warning that the digital therapy device does not represent a substitution for the patient's medication; and
(v)Physician labeling must include a summary of the clinical performance testing conducted with the device. [88 FR 2223, Jan. 13, 2023]
Connections5 cite this
Citation graph
cites case law
§ 882.5705
Digital therapy device to reduce sleep disturbance for psychiatric conditions.
Fed. Reg.×5
Cites 0Cited by 5 across 1 source
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.